Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03611816

Biological Bank for Atrial Fibrillation and Stroke

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years.

According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial fibrillation has significant genetic heterogeneity. About 40 genes have been identified as potentially involved. Studies have identified genes common to the risk of atrial fibrillation and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. The pathophysiology is not sufficiently understood to allow finding more effective therapies. It is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted.

The establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Stroke Arrhythmias, Cardiac Atrial Fibrillation Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Heart Diseases Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service neurologie Centre hospitalier Fleyriat, Bourg-en-Bresse, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Group 1a

  • Inclusion Criteria :
  • AF history
  • Exclusion Criteria :
  • No AF history
  • patient who didn't signed consent

Group 1b

  • Inclusion Criteria :
  • AF history
  • Scheduled electrophysiological exploration or AF ablation
  • Exclusion Criteria :
  • No AF history
  • pregnant women
  • patient who didn't signed consent

Group 1c

  • Inclusion Criteria :
  • AF/AT history
  • Stroke history
  • Exclusion Criteria :
  • No Stroke history
  • patient who didn't signed consent

Group 2

  • Inclusion Criteria :
  • patient over 80
  • ECG: sinusal rhythm
  • TTE : no left atrial dilatation
  • Exclusion Criteria :
  • atrial fibrillation history
  • TTE : Left atria >25cm², > 34m/m2), FEVG < 50%
  • ECG : QRS > 90 ms
  • cardiac pathologies (excepted hypertension and valvulopathies)
  • History of stroke and transient ischemic attack
  • patient who didn't signed consent

Group 3

  • Inclusion Criteria :
  • cryptogenic stroke or transient ischemic attack history before 50 yo
  • No AF history
  • Exclusion Criteria :
  • AF history
  • stroke or transient ischemic attack over 50 yo
  • patient who didn't signed consent

Treatment and study plan

Blood taken

Biological

Collection of clinical data

Blood taken

Genetic

Collection of DNA

Primary outcomes

  1. Quality of DNA sample

    Time frame: 1 day (the day of the storage)

    Quality is based on the measure of the purity of DNA with absorbance assay at 260/280nm on a spectrophotometer. For Plasma sample, purity is based on absence of hemolyzed blood by visual observation.

  2. Quality of Plasma sample

    Time frame: 1 day (the day of the storage)

    Quality is based on the purity of Plasma sample that is based on absence of hemolyzed blood by visual observation.

  3. Quality of preservation of the sample

    Time frame: 7 years (during all the duration of the collection)

    The quality of preservation of the sample throughout the conservation duration is based on the number of freezing/thawing of each cryotube that will be notified. As weel as any interruption in the freezing process (power failure, freezer failure).

Study contacts

Contact information is provided by the study sponsor or research team.

Elodie MOREL

CONTACT

[email protected]

04 72 35 73 81 ext. +33

Philippe CHEVALIER, PU-PH

CONTACT

[email protected]

04 72 35 70 27 ext. +33

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Biological Bank for Studies Related to Atrial Fibrillation and Stroke

Acronym: BAFA

Important dates

Study start
2018
Primary completion
2033
Study completion
2033
First posted
Aug 2, 2018
Registry last updated
Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.